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241In such patients, alternate modes of advanced therapies,
such as durable mechanical circulatory support (MCS), may
offer hope for life prolongation (7,8) and have thus been
used sporadically in highly-selected patients with varying
success (9,10). Yet, outcomes are unknown, and the safety
and appropriateness of MCS for patients with CCMP have
not been studied.
We, therefore, investigated the use of MCS in CCMP
patients, described their baseline characteristics and device
implantation strategies, and compared their outcomes with
those of patients with ischemic cardiomyopathy (ICMP)
and nonischemic cardiomyopathy (NICMP).RV = right ventricular
RVAD = right ventricular
assist device
Methods
Interagency Registry for Mechanically Assisted Circula-
tory Support. The Interagency Registry for Mechanically
Assisted Circulatory Support (INTERMACS) database is
a National Heart, Lung, and Blood Institute–funded
national registry of patients treated with U.S. Food and Drug
Administration–approved mechanical circulatory support
devices for the treatment of advanced heart failure (11).
Participation is mandatory for Centers for Medicare and
Medicaid Services–approved MCS implantation centers, all
information is audited, and a Medical Events Committee
reviews adverse events for medical reasonableness and
internal consistency. The University of Alabama was entrus-
ted with the Data Coordinating Center and has created and
maintained the registry since 2005.
Patient population. Using the INTERMACS registry, we
retrospectively identiﬁed prospectively entered patients with
CCMP who received MCS during the period of June 2006
through March 2011. To ensure that no patient was missed,
we included anthracyclines, doxorubicin, Adriamycin, and
chemotherapy as searchable terms in the database.
Patient characteristics and outcomes. We compared
CCMP patient pre-implant characteristics; implantation
strategies; and clinical, echocardiographic, and hemodynamic
proﬁles with those of patients with ICMP and NICMP.
The primary outcome was all-cause mortality, with data
censored at transplantation or device explantation after
myocardial recovery. Secondary outcomes were time to ﬁrst
major bleed, device malfunction, right ventricular (RV)
failure, infection, neurological dysfunction, and need for RV
assist device (RVAD) support at the time of or subsequent
to left ventricular assist device (LVAD) implantation.
Statistical analyses. Survival rates were calculated using the
Kaplan-Meier method. Categorical characteristics and
outcomes were compared using chi-square and Fisher exact
tests. Continuous variables were compared using the
Wilcoxon-Mann-Whitney test. Time-related events (death,
bleeding, device malfunction, infection, right heart failure,
and neurological dysfunction) were estimated using the
Kaplan-Meier method. Comparisons of freedom from event
curves were made using the log-rank test, which is the
univariate equivalent ofCox proportional analysis. Categoricalpre-implantation data were com-
pared across groups using the
chi-square test for equality of
proportions or, when the sample
size was small, the Fisher exact
test. Continuous pre-implantation
data were compared across groups
using a t test in the original scale or,
when appropriate, a t test after
arithmetic transformations for
skewed distributions. All analyses
were performed using SAS version
9.13 Unix statistical software
(SAS Institute Inc., Cary, North
Carolina).Results
We identiﬁed 75 patients (2%) from 3,812 patients
implanted between June 2006 and March 2011. Their
comparative pre-implantation characteristics are displayed in
Table 1. Female patients predominated in the CCMP group
(72%), whereas in the NICMP and ICMP groups, the
majority of patients were male (76% and 87%, respectively).
Patients with CCMP had generally fewer comorbidities than
both ICMP and NICMP patients, with lower rates of dia-
betes, alcohol abuse, and tobacco use. Of the 75 patients with
CCMP, 39 (52%) had a history of breast cancer, 25 (33%)
had lymphoma and other hematological cancers, 2 (3%) had
renal cancer, and 9 (12%) had unspeciﬁed malignancies.
There were no differences in the prevalence of New York
Heart Association functional class IV, patient proﬁles, ino-
trope use, or left ventricular ejection fraction severity. Also,
indexed left ventricular end-diastolic diameter was not
different between the groups.
The rate of use of automatic implantable deﬁbrillators was
66% in the CCMP group and 77% in both the ICMP and
NICMP groups (p ¼ 0.03).
In this series, 84% of CCMP patients were treated with
continuous ﬂow devices, which was not statistically different
from the ICMP (75%, p¼ 0.06) andNICMP(78%, p¼ 0.25)
patients.
Implantation strategy. CCMP patients were more likely
to have MCS implanted as destination therapy (33%)
compared with patients with both ICMP (14%, p < 0.0001)
and NICMP (23%, p < 0.03). If the implantation strategy
was a bridge to transplantation, there were no differences in
the rates of listing.
RV dysfunction. Surrogate markers of RV dysfunction
were signiﬁcantly more common in patients with CCMP
compared with ICMP and NICMP patients. Pulmonary
systolic pressures in the CCMP group were signiﬁcantly
lower than in both ICMP and NICMP patients (43.96 vs.
51.16 vs. 49.35 mm Hg, respectively; p ¼ 0.0015). Also,
right atrial pressure was higher (16.48 vs. 12.49 vs.
13.45 mm Hg, respectively; p ¼ 0.01) and severe tricuspid
Table 1 Baseline Characteristics of CCMP Compared With NICMP and ICMP Patients
CCMP
(n ¼ 75)
NICMP
(n ¼ 2,392) p Value
ICMP
(n ¼ 1,345) p Value
Demographic
White, % 64.0 64.0 0.92 80.0 0.0006
Male, % 28.0 76.0 <0.0001 87.0 <0.0001
Age, yrs 53.0 51.0 0.41 60.0 <0.0001
Married, % 63.0 62.0 0.76 72.0 0.12
Body mass index, kg/m2 26.0 28.9 <0.0001 28.0 0.0019
Body surface area, m2 1.84 2.09 <0.0001 2.08 <0.0001
Clinical, %
Diabetes 25.0 31.0 0.29 46.0 0.0004
Inotropes 89.0 83.0 0.18 80.0 0.06
Ascites 13.0 9.0 0.29 9.0 0.24
INTERMACS patient proﬁle level
1 20.0 22.0 0.67 20.0 0.99
2 47.0 43.0 0.55 42.0 0.39
3 20.0 19.0 0.39 19.0 0.33
4 7.0 10.0 0.34 13.0 0.33
5 1.0 2.0 0.61 3.0 0.61
6 1.0 1.0 0.95 2.0 0.84
7 0.0 1.0 0.36 1.0 0.33
Bridge to transplantation
Listed 35.0 42.0 0.21 34.0 0.98
Likely to be listed 19.0 27.0 0.10 27.0 0.12
Moderately likely to be listed 9.0 10.0 0.80 10.0 0.84
Unlikely to be listed 1.0 3.0 0.43 4.0 0.23
Destination therapy 33.0 14.0 <0.0001 23.0 0.03
NYHA functional class IV 84.0 81.0 0.55 83.0 0.85
Diagnosis coronary artery disease 0.0 16.0 0.0002 100.0 <0.0001
Cerebrovascular accident 7.0 7.0 0.93 8.0 0.69
Transient ischemic attack 7.0 3.0 0.12 4.0 0.27
Cancer 89.0 4.0 <0.0001 7.0 <0.0001
Current smoker 1.0 12.0 0.01 15.0 0.0016
Current drug abuse 1.0 3.0 0.45 2.0 0.87
Alcohol abuse history 5.0 16.0 0.01 18.0 0.01
Blood type O 62.0 74.0 0.07 45.0 0.0049
Rheumatological disease 3.0 5.0 0.42 4.0 0.67
Hepatitis B 0 1.0 0.31 2.0 0.26
Hepatitis C 4.0 2.0 0.17 2.0 0.30
Dialysis 1.0 3.0 0.37 2.0 0.56
History of coronary artery bypass graft 1.0 8.0 0.03 43.0 <0.0001
Implantable cardioverter-deﬁbrillator 66.0 77.0 0.03 77.0 0.03
Intra-aortic balloon pump 32.0 35.0 0.59 36.0 0.48
Ventilator 9.0 12.0 0.48 12.0 0.48
Peripheral vascular disease 3.0 4.0 0.54 10.0 0.04
Carotid artery disease 4.0 5.0 0.81 17.0 0.01
Beta-blockers 82.0 74.0 0.12 75.0 0.18
ACE inhibitors 68.0 53.0 0.02 51.0 0.01
Continued on the next page
Oliveira et al. JACC Vol. 63, No. 3, 2014
Mechanical Circulatory Support in Chemotherapy-Induced Cardiomyopathy January 28, 2014:240–8
242regurgitation was more common in CCMP patients (62.3%
vs. 48.8% vs. 43.3%, respectively; p ¼ 0.003). Concordantly,
the central venous pressure/pulmonary capillary wedge
pressure ratio, a useful predictor of RV dysfunction when
>0.63, was signiﬁcantly higher in CCMP patients compared
with both NICMP and ICMP patients (0.68 vs. 0.54 vs.
0.51, respectively; p < 0.0001). Cardiac index and left
ventricular ejection fraction did not differ among the groups,although heart rate was signiﬁcantly higher in the CCMP
group. Last, aspartate aminotransferase and alanine amino-
transferase were twice as high in CCMP patients compared
with ICMP patients and >1.5 times higher than in NICMP
patients, but the differences were not statistically signiﬁcant.
Because actual RV risk scores could not be calculated for
individual patients, comparisons of surrogate markers of RV
dysfunction between the 3 groups are shown in Table 2.
Table 1 Continued
CCMP
(n ¼ 75)
NICMP
(n ¼ 2,392) p Value
ICMP
(n ¼ 1,345) p Value
Laboratory
Sodium, mmol/l 133 134 0.19 134 0.03
Creatinine, mg/dl 1.4 1.5 0.30 1.5 0.19
Blood urea nitrogen, mg/dl 28 30 0.26 32 0.06
Total bilirubin, mg/dl 1.5 1.6 0.56 1.4 0.27
Cholesterol, mg/dl 137 124 0.12 127. 0.24
INR, IU 1.28 1.41 0.0009 1.34 0.14
Hemoglobin, mg/dl 11.0 11.4 0.10 11.0 0.83
Platelet, K/ml 203 201 0.79 195 0.40
Protein C, % 72 83 0.53 81 0.63
Protein S, % 37 78 0.01 79 0.04
C-reactive protein, mg/l 16.9 20.4 0.81 24.1 0.71
B-type natriuretic peptide, pg/ml 1,762 1,333 0.06 1,191 0.01
Aspartate aminotransferase, mg/l 220 125 0.52 90 0.38
Alanine aminotransferase, mg/l 199 125 0.19 96 0.38
White blood cells, K/ml 8.4 9.1 0.06 9.2 0.04
Albumin, g/dl 3.3 3.3 0.87 3.2 0.43
Pre-albumin, mg/dl 18.3 17.9 0.79 17.5 0.61
Hemodynamics
Systolic blood pressure, mm Hg 100 100 0.76 102 0.22
Diastolic blood pressure, mm Hg 63 63 0.70 62 0.22
Cardiac index, l/min/m2 2.0 2.1 0.70 2.2 0.21
Heart rate, beats/min 100 91 0.0001 87 <0.0001
Right atrial pressure, mm Hg 16.5 13.5 0.01 12.5 0.0001
LVEDD, cm 5.89 6.95 <0.0001 6.73 <0.0001
Pulmonary wedge pressure, mm Hg 24.1 25.0 0.56 24.4 0.85
Pulmonary systolic pressure, mm Hg 43.9 49.4 0.0015 51.2 <0.0001
Pulmonary diastolic pressure, mm Hg 25.0 26.1 0.39 25.4 0.75
Pulmonary vascular resistance using
cardiac output, Woods units
2.4 2.9 0.25 2.7 0.46
Mitral regurgitation (moderate/severe), % 68.0 61.0 0.28 56.0 0.08
Tricuspid regurgitation (moderate/severe), % 62.0 43.0 0.0037 49.0 0.04
Aortic regurgitation (moderate/severe), % 7.0 5.0 0.60 5.0 0.63
Left ventricular ejection fraction, % 25.9 14.0 0.38 25.7 0.48
Left ventricular ejection fraction (<20 severe), % 74.0 70.0 0.48 7.0 0.91
Right ventricular ejection fraction (severe), % 27.0 27.0 1.00 24.0 0.63
Operative, %
Concomitant surgery 48.0 36.0 0.04 36.0 0.04
Left ventricular continuous ﬂow device 84.0 74.0 0.06 78.0 0.25
Failure to wean from cardiopulmonary bypass 5.0 1.0 0.01 2.0 0.04
ACE ¼ angiotensin-converting enzyme; CCMP ¼ chemotherapy-induced cardiomyopathy; ICMP ¼ ischemic cardiomyopathies; INR ¼ international
normalized ratio; INTERMACS ¼ Interagency Registry for Mechanically Assisted Circulatory Support; LVEDD ¼ left ventricular end-diastolic dimension;
NICMP ¼ nonischemic cardiomyopathies; NYHA ¼ New York Heart Association.
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243Need for RVAD. Pre-operative RV failure resulted in
concomitant RVAD implantation at the time of MCS
surgery in 11 CCMP patients (14%), whereas post-LVAD
RV failure required subsequent RVAD placement in
another 3 CCMP patients (4%). Compared with all others,
patients with CCMP had an increased need for RVAD
(19% vs. 9.3%, p < 0.0001). When compared separately, the
difference in RVAD need remained signiﬁcant in CCMP,
NICMP, and ICMP patients (19%, 11%, and 6%, respec-
tively; p ¼ 0.006) (Fig. 1). Interestingly, in this cohort, no
total artiﬁcial hearts were implanted in CCMP patients as
a bridge to transplantation.Concomitant surgery and operative factors. Patients with
CCMP had more concomitant surgery (48%) than patients
with NICMP (36.5%; p¼ 0.03) and ICMP (36%; p¼ 0.04).
Of these, tricuspid repair was the most common (n ¼ 11;
15%), followed by RVAD implantation (n ¼ 6; 8%), atrial
septal defect closure (n ¼ 4; 5%), and other (n ¼ 18; 24%).
Other concomitant surgeries included removal of temporary
support devices (n¼ 7), aortic valve closure (n¼ 4), left atrial
appendectomy (n ¼ 2), femoral artery repair (n ¼ 2), peri-
cardial reconstruction (n¼ 2), and LV mass removal (n¼ 1).
CCMP patients were more likely to fail weaning from
cardiopulmonary bypass compared with both NICMP and
Table 2 Surrogate Markers of Right Ventricular Function Among CCMP, NICMP, and ICMP
CCMP
(n ¼ 75)
NICMP
(n ¼ 2,392) p Value
ICMP
(n ¼ 1,345) p Value
Inotropes, % 89.0 83.0 0.18 80.0 0.06
Ascites 13.0 9.0 0.29 9.0 0.24
Sodium, mmol/l 133 134 0.19 134 0.03
Creatinine, mg/dl 1.4 1.5 0.30 1.5 0.19
Blood urea nitrogen, mg/dl 28.0 30.6 0.26 32.06 0.06
Total bilirubin, mg/dl 1.5 1.6 0.56 1.4 0.27
Aspartate aminotransferase, m/l 220 125 0.52 90 0.38
Alanine aminotransferase, m/l 200 126 0.19 96 0.38
Systolic blood pressure, mm Hg 100 100 0.76 102 0.22
Diastolic blood pressure, mm Hg 63 63 0.70 62 0.22
Cardiac index, l/min/m2 2.0 2.1 0.70 2.2 0.21
Heart rate, beats/min 100 92 0.0001 87 <0.0001
Right atrial pressure, mm Hg 16 13 0.01 12 0.0001
Pulmonary wedge pressure, mm Hg 24 25 0.56 24 0.85
CVP/PCWP ratio 0.68 0.54 <0.0001 0.51 <0.0001
Pulmonary systolic pressure, mm Hg 44 49 0.0015 51 <0.0001
Pulmonary diastolic pressure, mm Hg 25 26 0.39 25 0.75
Tricuspid regurgitation (moderate/severe), % 62.0 43.0 0.0037 49.0 0.04
Right ventricular ejection fraction (severe), % 27.0 27.0 1.00 24.0 0.63
Failure to wean from cardiopulmonary bypass, % 5.0 1.0 0.01 2.0 0.04
CVP ¼ central venous pressure; PCWP ¼ pulmonary capillary wedge pressure; other abbreviations as in Table 1.
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244ICMP patients (5.3% vs. 1.5% vs. 1.9%, respectively;
p ¼ 0.01 and 0.04, respectively).
The rate of continuous ﬂow device use was the same in
CCMP, NICMP, and ICMP patients (84%, 74.5%, and
78.4%, respectively).
Clinical outcomes and adverse events. Table 3 illustrates
comparative outcomes in all groups. There was an increased
risk of bleeding in CCMP patients compared with both
ICMP and NICMP patients, but there was no difference in
the time to neurological dysfunction, device malfunction,
infection, or RV failure events (Fig. 2).
Survival. Survival of CCMP patients who received LVAD
support was equivalent to that of other MCS patients.Figure 1
Need for RVAD Use According to Etiology
of Cardiomyopathy
Incidence of need for RVAD use according to etiology of cardiomyopathy.
CCMP¼ chemotherapy-induced cardiomyopathy; ICMP¼ ischemic cardiomyopathy;
NICMP ¼ nonischemic cardiomyopathy; RVAD ¼ right ventricular assist device.Survival in the groups is illustrated in Figure 3. CCMP
patients who received biventricular assist device support did
signiﬁcantly worse than those who only received an LVAD.
There was no signiﬁcant difference in the rates of death,
transplantation, or recovery in any of the 3 groups (Table 3).
When cause of death was analyzed, there were 18 deaths
in the CCMP group: multiorgan failure (n ¼ 5; 28%), renal
failure (n ¼ 2; 11%), hemorrhage (n ¼ 2; 11%), cerebro-
vascular event (n ¼ 2; 11%), abdominal compartment
syndrome (n ¼ 1; 6%), pump failure (n ¼ 2; 11%), cancer
(n ¼ 1; 6%), respiratory failure (n ¼ 1; 6%), anoxic brain
injury (n ¼ 1; 6%), and sudden/unexplained (n ¼ 1; 6%). Of
these 18 deaths, 6 (33%) occurred among the 14 biven-
tricular assist device patients.
Discussion
This is the ﬁrst report to date of a series of CCMP patients
treated with MCS. We have found that survival of CCMP
patients treated with MCS is similar to that of other MCS
patients, but that CCMP is associated with a signiﬁcantly
higher risk of RV failure and need for RVAD support.Table 3 Clinical Outcomes of All Groups
Outcome
CCMP
(n ¼ 75)
ICMP
(n ¼ 1,345)
NICMP
(n ¼ 2,466)
Total
(N ¼ 3,812)
Death 19 (25) 294 (22) 466 (19) 761 (20)
Transplantation 22 (29) 432 (32) 864 (36) 1,296 (34)
Recovery 1 (1) 3 (0.2) 41 (1) 44 (1)
Alive 33 (44) 616 (46) 1,095 (45) 1,711 (45)
Values are n (%). CCMP versus ICMP: p ¼ 0.29; CCMP versus NICMP: p ¼ 0.51; ICMP versus NICMP:
p < 0.0001.
Abbreviations as in Table 1.
Figure 2 Adverse Events in Patients With CCMP
(A) Time to ﬁrst bleeding. (B) Time to ﬁrst infection. (C) Time to ﬁrst neurological dysfunction. (D) Time to ﬁrst device malfunction. (E) Time to ﬁrst right heart failure event.
RHF ¼ right heart failure; other abbreviations as in Figure 1.
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245Therefore, while validating the usefulness of this technology
for CCMP patients, we also demonstrate the prevalence of
biventricular involvement in CCMP.
In this study, almost 1 in 5 patients with CCMP had
RV failure that required RVAD support. Most likely, this
high incidence reﬂects the learning curve in evaluating and
avoiding RV failure, which has steadily improved over the
time period studied. Other ﬁndings supportive of the
higher frequency of RV involvement in CCMP were more
frequent surrogate markers of RV dysfunction (12) and
a higher incidence of preoperative severe tricuspid regur-
gitation (13,14) requiring tricuspid valve repair. Although
the adverse event comparison appears to negate this
assertion, it is important to remember that, in the adverse
event analysis, RV failure is only considered post-operatively. This means that it also includes patients who
had already received RVADs and were no longer at risk of
RV failure.
The discovery that RV failure occurs in about one-ﬁfth
of CCMP patients is unique given that, in most car-
diomyopathic processes, the pathogenesis of myocardial
dysfunction has been shown to predominantly affect the
left ventricle (15) and that w90% of MCS patients can be
treated with LVAD alone (16). Therefore, this knowledge
should lead to increased awareness of the possibility of
post-implantation RV failure when deciding to treat
CCMP patients with MCS. Indeed, pre-emptive RVAD
placement or the use of a total artiﬁcial heart may be
preferred for these patients to avoid the increased morbidity
and mortality associated with post-LVAD RV failure
Figure 3 Survival of Patients With CCMP
(A) CCMP. (B) CCMP versus (ICMP and NICMP) adult primary implants. (C) CCMP versus ICMP versus NICMP adult primary implants. (D) CCMP patients by device strategy.
(E) CCMP patient proﬁle. (F) CCMP by device side. BTT ¼ bridge to transplantation; BiVAD ¼ biventricular assist device; LVAD ¼ left ventricular assist device; other
abbreviations as in Figure 1.
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246(17,18). This may be especially relevant in the setting of
heart failure caused speciﬁcally by anthracyclines. Because
anthracyclines such as doxorubicin were the cause of
CCMP in our entire patient population, it is likely that
increased RV failure is a feature more speciﬁc to anthra-
cyclines than other agents, such as trastuzumab. Therefore,
it may become important to determine with certainty the
etiology of CCMP because, if the etiology is anthracyclines,
RV function is likely to deteriorate proportionately to the
left ventricular function, and univentricular support may
not sufﬁce. RV endomyocardial biopsy with typical char-
acteristics of anthracycline cardiotoxicity is the only way to
establish with certainty the etiology of heart failure in
patients with CCMP (19–21), particularly because many
potentially cardiotoxic agents are given simultaneously or in
sequence to treat cancer. The pathological proof ofanthracycline cardiotoxicity may therefore be instrumental
in the decision-making process leading to the use of
biventricular support. Conversely, biopsy determination of
the absence of anthracycline injury, together with other
measures of RV function, may help avoid unnecessary
RVAD use, especially because, as previously shown (16)
and demonstrated here, the need for biventricular assist
device support portends a poorer prognosis. Unfortunately,
optimal treatment of CCMP patients with severe RV failure
continues to be limited by the absence of a commercially
available U.S. Food and Drug Administration–approved
durable intracorporeal RVAD. Indeed, in this cohort,
patients who required RVAD support were treated with
temporary paracorporeal systems.
This study conﬁrms that the overwhelming majority of
patients with CCMP who receive advanced heart failure
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247therapy are women, comprising about three-fourths of the
patients in this cohort (5). Although the most likely expla-
nation is the high prevalence of breast cancer survivors in
this cohort, it is possible that women are more prone to the
cardiotoxic effects of cancer therapy or that in women, the
progression to end-stage heart failure is more common. If
conﬁrmed by future studies, increased monitoring and
more robust cardioprotective measures, including consi-
deration of prophylactic beta-blocker and angiotensin-
converting enzyme inhibitor therapy, should be considered
in women undergoing potentially cardiotoxic cancer
treatment.
Although this study does not allow deﬁnitive conclusions
that can be generalized about the characteristics of CCMP
patients because this cohort is clearly not representative of
the majority of patients with CCMP, it does provide
important insights into physicians’ patterns of practice
relating to CCMP patients. A provocative observation is
that despite being younger and having equivalent ejection
fraction and heart failure severity, CCMP patients had
signiﬁcantly lower use of a prophylactic implantable
cardioverter-deﬁbrillator compared with both ICMP and
NICMP patients. A possible explanation for this ﬁnding is
that these patients may present too acutely for implantation
of cardioverter-deﬁbrillators. Also, CCMP patients selected
for MCS had signiﬁcantly lower use of alcohol, drugs, and
tobacco as well as lower rates of diabetes. It is possible that,
in general, CCMP patients display healthier behavior that
stems from the fear of recurrent cancer, but it is also not
inconceivable that because of the stigma associated with the
etiology of their heart failure, they may be subjected to
stricter requirements for MCS eligibility than their ICMP
and NICMP counterparts. Last, the implantation strategy
for CCMP patients was destination therapy much more
frequently than for both NICMP and ICMP patients. This
is likely a result of the usual 5-year cancer-free requirement
for transplantation eligibility, as well as the type of previous
cancers: some, like melanoma, may confer deﬁnitive ineli-
gibility. Accordingly, our data show that if the original
implantation strategy was a bridge to transplantation,
CCMP patients were as likely as any other to be listed for
transplantation.
Unexpectedly, there was no difference in the rates of post-
implantation infections between the groups, although
CCMP patients undergoing heart transplantation have been
shown to be more prone to infectious complications (5).
There was, however, increased bleeding in the CCMP
group, but platelet levels, international normalized ratios,
and protein C levels were similar. Protein S, however, was
signiﬁcantly lower in CCMP patients compared with both
ICMP and NICMP patients. Higher, but not lower, protein
S levels have been shown to be correlated with bleeding (22),
and thus the lower levels of protein S in CCMP patients do
not explain their increased bleeding risk. Although we found
no differences in pre-implantation bleeding risk factors
among the groups, it is possible that the higher rates ofbleeding in CCMP patients are due to chemotherapy-
induced bone marrow toxicity with decreased reserve.
However, a more likely explanation is that patients who go
into surgery more “congested,” with higher central venous
pressure, have been shown, at least anecdotally, to have more
perioperative bleeding. Despite increased bleeding, only 2
patients died of hemorrhage, and overall comparative
survival in CCMP patients was not adversely affected.
Study limitations. There are several limitations inherent to
the database itself and to this type of study. One major
imperfection of the database is illustrated here by the fact
that the presence of cancer was only documented in 89% of
patients with a history of anthracycline therapy. Because
there are no other medical indications for anthracycline use,
rather than suggesting that 11% of patients did not have
cancer, this discrepancy only illustrates the incompleteness
of cancer-related data entry for these patients. Accordingly,
there are no reliable data on the type of cancer and, many
times, the type of chemotherapy used, as well as the
temporal relationship between chemotherapy and heart
failure development. In fact, the attribution of heart failure
etiology cannot be veriﬁed with certainty in the absence of
biopsy data. Additionally, because patient identiﬁcation
information was not collected to protect patient privacy, the
registry is unable to conﬁrm death or heart transplantation
with external sources such as the Social Security Death
Index and the United Network of Organ Sharing database.
Last, despite being the largest such series, the total number
of patients with CCMP remains small, which may have
hindered our ability to detect survival differences between
CCMP patients and other groups.
Conclusions
CCMP patients treated with MCS have survival similar to
that of other MCS patients despite having more frequent
need of an RVAD and increased bleeding risk. Further
studies are needed to better understand the nature of CCMP
and to conﬁrm our ﬁndings.
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